SEARCH

SEARCH BY CITATION

References

  • Allain P., Le Bouil A., Cordillet E., Le Quay L., Bagheri H. and Montastruc J. L. (1995) Sulfate and cysteine levels in the plasma␣of␣patients with Parkinson's disease. Neurotoxicology 16, 527529.
  • Andersson A., Brattstrom L., Israelsson B., Isaksson A., Hamfelt A. and Hultberg B. (1992) Plasma homocysteine before and after methionine loading with regard to age, gender, and menopausal status. Eur. J. Clin. Invest. 22, 7987.
  • Andrews A. M. and Murphy D. L. (1993) Sustained depletion of cortical and hippocampal serotonin and norepinephrine but not striatal dopamine by 1-methyl-4-(2′-aminophenyl)-1,2,3,6-tetrahydropyridine (2′-NH2-MPTP): a comparative study with 2′-CH3-MPTP and MPTP. J. Neurochem. 60, 11671170.
  • Barrientos A. and Moraes C. T. (1999) Titrating the effects of mitochondrial complex I impairment in the cell physiology. J. Biol. Chem. 274, 1618816197.
  • Van Den Berg M., Van Der Knaap M. S., Boers G. H., Stehouwer C. D., Rauwerda J. A. and Valk J. (1995) Hyperhomocysteinaemia; with reference to its neuroradiological aspects. Neuroradiology 37, 403411.DOI: 10.1007/s002340050119
  • Betarbet R., Sherer T. B., MacKenzie G., Garcia-Osuna M., Panov A. V. and Greenamyre J. T. (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3, 13011306.
  • Bezard E., Dovero S., Bioulac B. and Gross C. (1997) Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp. Neurol. 148, 288292.
  • Blount B. C., Mack M. M., Wehr C. M., MacGregor J. T., Hiatt R. A., Wang G., Wickramasinghe S. N., Everson R. B. and Ames B. N. (1997) Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implication for cancer and neuronal damage. Proc. Natl Acad. Sci. USA 94, 32903295.
  • Brattstrom L., Lindgren A., Israelsson B., Andersson A. and Hultberg B. (1994) Homocysteine and cysteine: determinants of plasma levels␣in middle aged and elderly subjects. J. Intern. Med. 236, 633641.
  • Double K. L., Gerlach M., Youdim M. B. and Riederer P. (2000) Impaired iron homeostasis in Parkinson's disease. J. Neural. Transm. Supplement 60, 3758.
  • Duan W. and Mattson M. P. (1999) Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease. J.␣Neurosci. Res. 57, 195206.
  • Duan W., Zhang Z., Gash D. M. and Mattson M. P. (1999) Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann. Neurol. 46, 587597.DOI: 10.1002/1531-8249(199910)46:4<587::AID-ANA6>3.0.CO;2-M
  • Elkind M. S. and Sacco R. L. (1998) Stroke risk factors and stroke prevention. Semin. Neurol. 18, 429440.
  • Finkelstein J. D. (1990) Methionine metabolism in mammals. J. Nutr. Biochem. 1, 228237.
  • Gibb W. R., Costall B., Domeney A. M., Kelly M. E. and Naylor R. J. (1988) The histological effects of intracerebral injection or infusion of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and MPP+ (1-methyl-4-phenylpyridinium) in rat and mouse. Brain. Res. 461, 361366.
  • Giles W. H., Kittner S. J., Anda R. F., Croft J. B. and Casper M. L. (1995) Serum folate and risk for ischemic stroke. First National Health and Nutrition Examination Survey epidemiologic follow-up study. Stroke 26, 11661170.
  • Greenblatt J. M., Huffman L. C. and Reiss A. L. (1994) Folic acid in neurodevelopment and child psychiatry. Prog. Neuropsychopharmacol. Biol. Psychiatry 18, 647660.
  • Grieve A., Butcher S. P. and Griffiths R. (1992) Synaptosomal plasma membrane transport of excitatory sulphur amino acid transmitter candidates: kinetic characterisation and analysis of carrier specificity. J. Neurosci. Res. 32, 6068.
  • Guo Q., Sebastian L., Sopher B. L., Miller M. W., Glazner G. W., Ware C. B., Martin G. M. and Mattson M. P. (1999) Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation. Proc. Natl Acad. Sci. USA 96, 41254130.
  • Hengemihle J. M., Long J. M., Betkey J., Jucker M. and Ingram D. K. (1999) Age-related psychomotor and spatial learning deficits in 129/SvJ mice. Neurobiol. Aging 20, 918.
  • Jenner P. and Olanow C. W. (1998) Understanding cell death in Parkinson's disease. Ann. Neurol. 44, S72S84.
  • Kruman I., Bruce-Keller A. J., Bredesen D. E., Waeg G. and Mattson M.␣ P. (1997) Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis. J. Neurosci. 17, 50895100.
  • Kruman I. I., Culmsee C., Chan S. L., Kruman Y., Guo Z., Penix L. and Mattson M. P. (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci. 20, 69206926.
  • Kuhn W., Roebroek R., Blom H., Van Oppenraaij D., Przuntek H., Kretschmer A., Buttner T., Woitalla D. and Muller T. (1998) Elevated plasma levels of homocysteine in Parkinson's disease. Eur. Neurol. 40, 225227.
  • Langston J. W. (1987) Parkinson's disease: current view. Am. Fam. Phys. 35, 201206.
  • Langston J. W. (1998) Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann. Neurol. 44, S45S52.
  • Le Couteur D. G., McLean A. J., Taylor M. C., Woodham B. L. and Board P. G. (1999) Pesticides and Parkinson's disease. Biomed. Pharmacother. 53, 122130.
  • Lipton S. A., Kim W. K., Choi Y. B., Kumar S., D'Emilia D. M., Rayudu P. V., Arnelle D. R. and Stamler J. S. (1997) Neurotoxicity␣associated with dual actions of homocysteine at the N-methyl-d-aspartate receptor. Proc. Natl Acad. Sci. USA 94, 59235928.
  • Logroscino G., Marder K., Cote L., Tang M. X., Shea S. and Mayeux R. (1996) Dietary lipids and antioxidants in Parkinson's disease:␣a␣population-based, case-control study. Ann. Neurol. 39, 8994.
  • Lucock M. (2000) Folic acid: nutritional biochemistry, molecular biology, and role in disease processes. Mol. Genet. Metab. 71, 121138.
  • Marsden C. D. (1994) Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 57, 672681.
  • Meleady R. A. and Graham I. M. (1998) Homocysteine and vascular disease: nature or nurture? J. Cardiovasc. Risk 5, 233237.
  • Miller J. W., Shukitt-Hale B., Villalobos-Molina R., Nadeau M. R., Selhub J. and Joseph J. A. (1997) Effect of 1-dopa and the catechol-O-methyltransferase inhibitor Ro 41–0960 on sulfur amino acid metabolites in rats. Clin. Neuropharmacol. 20, 5566.
  • Moratalla R., Quinn B., DeLanney L. E., Irwin I., Langston J. W. and Graybiel A. M. (1992) Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl Acad. Sci. USA 89, 38593863.
  • Muller T., Woitalla D., Hauptmann B., Fowler B. and Kuhn W. (2001) Decrease of methionine and S-adnenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci. Lett. 308, 5456.
  • Refsum H., Ueland P. M., Nygard O. and Vollset S. E. (1998) Homocysteine and cardiovascular disease. Annu. Rev. Med. 49, 3162.
  • De Rijk M. C., Breteler M. M., Den Breeijen J. H., Launer L. J., Grobbee D. E., Van Der Meche F. G. and Hofman A. (1997) Dietary antioxidants and Parkinson disease. The Rotterdam Study. Arch. Neurol. 54, 762765.
  • Schneider J. S., Yuwiler A. and Markham C. H. (1987) Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons␣in the monkey following exposure to MPTP. Brain Res. 411, 144150.
  • Scott J. M. and Weir D. G. (1998) Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry. J.␣Cardiovasc. Risk 5, 223227.
  • Seaton T. A., Cooper J. M. and Schapira A. H. (1998) Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Res. 809, 1217.
  • De Silva H. R., Khan N. L. and Wood N. W. (2000) The genetics of Parkinson's disease. Curr. Opin. Genet. Dev. 10, 292298.
  • Surtees R., Bowron A. and Leonard J. (1997) Cerebrospinal fluid and plasma total homocysteine and related metabolites in children with cystathionine β-synthase deficiency: the effect of treatment. Pediatr. Res. 42, 577582.
  • Tatton N. A. (2000) Increased caspase 3 and bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp. Neurol. 166, 2943.
  • Taylor C. A., Saint-Hilaire M. H., Cupples L. A., Thomas C. A., Burchard A. E., Feldman R. G. and Myers R. H. (1999) Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. Am. J. Med. Genet. 88, 742749.
  • Tella S. R., Ladenheim B., Andrews A. M., Goldberg S. R. and Cadet J.␣ L. (1996) Differential reinforcing effects of cocaine and GBR-12909: biochemical evidence for divergent neuroadaptive changes in the mesolimbic dopaminergic system. J. Neurosci. 16, 74167427.
  • Watkins D. and Rosenblatt D. S. (1989) Functional methionine synthase deficiency (cblE and cblG): clinical and biochemical heterogeneity. Am. J. Med. Genet. 34, 427434.
  • Welch G. N. and Loscalzo J. (1998) Homocysteine and atherothrombosis. N. Engl. J. Med. 338, 10421050.
  • Yasui K., Kowa H., Nakaso K., Takeshima T. and Nakashima K. (2000) Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 55, 437440.
  • Yu Z. F., Bruce-Keller A. J., Goodman Y. and Mattson M. P. (1998) Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J.␣Neurosci. Res. 53, 613625.